US › Healthcare

Intensity Therapeutics, Inc. Common stock (INTS)

US · Healthcare · Biotechnology

$4.18-1.88%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-2.4M

Profit YoY

+27.3%

EPS

$-0.96

EPS estimate

$-1.09

EPS came in at -0.96 against a street estimate of -1.09 — a beat of 11.9%.

Key statistics

Market cap

$11.5M

Forward P/E

0.0

P/B

1.12

Book value

$3.93

EPS (TTM)

$-4.01

52-week high

$43.50

52-week low

$3.51

50-day MA

$4.30

200-day MA

$7.37

Beta

3.03

Analyst view

Analysts rate Intensity Therapeutics, Inc. Common stock a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $24.80.

Shareholding

Insiders

4.55%

Institutions

7.01%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.96%
Vanguard Group Inc	0.96%
NANO CAP NEW MILLENNIUM GROWTH FUND L P	0.93%
Sentinus, LLC	0.86%
Vanguard Capital Management, LLC	0.62%
Mesirow Fin Investmt Mgmt Intl Equity	0.52%
Vanguard Fiduciary Trust Co	0.34%
Goss Wealth Management LLC	0.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Intensity Therapeutics, Inc. Common stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.